Differential effects of exogenous interleukin-10 on cardiac allograft survival: Inhibition of rejection by recipient pretreatment reflects impaired host accessory cell function

Transplantation

Volumn 68, Issue 9, 1999, Pages 1402-1409

  Li, Wei ^a   Fu, Fumin ^a   Lu, Lina ^a   Narula, Satwant K ^b   Fung, John J ^a   Thomson, Angus W ^a   Qian, Shiguang ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; INTERLEUKIN 10; TACROLIMUS;

ACCESSORY CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; EFFECTOR CELL; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0033571552     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199911150-00029     Document Type: Article

References (41)

1. Bejarano MT, de Waal Malefyt R, Abrams JS, et al. Interleukin-10 inhibits allogeneic proliferative and cytotoxic T cell responses generated in primary mixed lymphocyte cultures. Int Immunol 1992; 4: 1389.
2. + T-cell clones and resting T cells: specific inhibition of IL-2 production and proliferation. J Immunol 1993; 150: 4754.
3. de Waal Malefyt R, Haanen J, Spits H, et al. Interleukin-10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174: 915.
4. Ding L, Shevach EM. IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function. J Immunol 1992; 148: 3133.
5. Beissert S, Hosoi J, Grabbe S, Asahina A, Granstein RD. IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells. J Immunol 1995; 154: 1280.
6. Steinbrink K, Wölfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997; 159: 4772.
7. de Waal Malefyt R, Moore KW. Interleukin-10. In: Thomson, AW, ed. The cytokine handbook, 3rd Ed. San Diego: Academic Press, 1998: 333.
8. D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon-y-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993; 178: 1041.
9. Qian S, Li W, Li Y, et al. Systemic administration of cellular interleukin-10 exacerbates cardiac allograft rejection in mice. Transplantation 1996; 62: 1709.
10. Li W, Lu L, Li Y, et al. High-dose cellular IL-10 exacerbates rejection and reverses effects of cyclosporine and tacrolimus in mouse cardiac transplantation. Transplant Proc 1997; 29: 1081.
11. Blazar BR, Taylor PA, Smith S, Vallera DA. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts. Blood 1995; 85: 842.
12. Berman RM, Suzuki T, Tahara H, Robbins P, Narula SK, Lotze MT. Systemic administration of cellular interleukin-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J Immunol 1996; 157: 231.
13. Ono K, Lindsey ES. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg 1969; 7: 225.
14. Vieira P, de Waal-Malefyt R, Dang M-N, et al. Isolation and expression of human cytokine synthesis inhibitory factor (CSIF/IL-10) cDNA clones: homology to Epstein-Barr virus open reading frame BCRF1. Proc Natl Acad Sci USA 1991; 88: 1172.
15. Lu L, Li W, Fu F, et al. Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival. Transplantation 1997; 64: 1808.
16. Lu L, Woo J, Rao AS, et al. Propagation of dendritic cell progenitors from normal mouse liver using GM-CSF and their maturational development in the presence of type-1 collagen. J Exp Med 1994; 179: 1823.
17. Lowry RP, Konieczy B, Alexander D, et al. Interleukin-10 eliminates anti-CD3 monoclonal antibody-induced mortality and prolongs heart allograft survival in inbred mice. Transplant Proc 1996; 27: 392.
18. Wissing KM, Morelon E, Legendre C, et al. A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapy. Transplantation 1997; 64: 999.
19. Xu G-P, Sharma VK, Li B, et al. Intragraft expression of IL-10 messenger RNA: a novel correlate of renal allograft rejection. Kidney Int 1995; 48: 1504.
20. + graft-infiltrating T lymphocytes in promptly rejected kidney allografts. Transplantation 1995; 59: 1113.
21. Rabinovitch A, Suarez-Pinzon WL, Sorensen O, et al. Combination therapy with cyclosporine and interleukin-4 or interleukin-10 prolongs survival of syngeneic pancreatic islet grafts in non-obese diabetic mice. Transplantation 1997; 64: 1525.
22. Rabinovitch A, Suarez-Pinzon WL, Sorensen O, et al. Combined therapy with interleukin-4 and interleukin-10 inhibits autoimmune diabetes recurrence in syngeneic islet-transplanted non-obese diabetic mice. Transplantation 1995; 60: 368.
23. Zheng XX, Steele AW, Nickerson PU, et al. Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation. J Immunol 1995; 154: 5590.
24. MacNeil TA, Suda T, Moore KW, Mosmann TR, Zlotnik A. IL-10, a novel growth cofactor for mature and immature T cells. J Immunol 1990; 145: 4167.
25. Chen WF, Zlotnik A. Interleukin 10: a novel cytotoxic T cell differentiation factor. J Immunol 1991; 147: 528.
26. Thompson-Snipes L, Dhar V, Bond MW, Mosmann TR, Moore KW, Rennick DM. Interleukin 10: a novel stimulatory factor for mast cells and their progenitors. J Exp Med 1991; 173: 507.
27. Rousset F, Garcia E, Defrance T, et al. Interleukin-10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992; 89: 1890.
28. Berman R, Suzuki T, Tahara H, Robbins P, Lotze MT. Human and viral interleukin-10 (hIL-10 and vIL-10) mediate opposing effects in tumor immunity. Cytokine 1994; 6: 571 [Abstract].
29. Schwartz MA, Hamilton LD, Tardelli L, Narula SK, Sullivan LM. Stimulation of cytotoxic activity by interleukin-10. J Immunother 1994; 16: 95.
30. + T lymphocyte migration. J Immunol 1993; 151: 4545.
31. Taga K, Cherney B, Tosato G. IL-10 inhibits apoptotic cell death in human T cells starved of IL-2. Int Immunol 1993; 12: 1599.
32. Levi Y, Brouet JC. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J Clin Invest 1994; 93: 424.
33. Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993; 151: 1224.
34. Willems F, Marchant A, Delville JP, et al. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur J Immunol 1994; 24: 1007.
35. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389: 737.
36. Macatonia SE, Doherty TM, Knight SC, O'Garra A. Differential effect of IL-10 on dendritic cell-induced T cell proliferation and IFN-γ production. J Immunol 1993; 150: 3755.
37. Meyaard L, Hovenkamp E, Otto SA, Miedema F. IL-12-induced IL-10 production by human T cells as a negative feedback for IL-12-induced immune responses. J Immunol 1996; 156: 2776.
38. Liu Z, Sun YK, Xi YP, et al. Contribution of direct and indirect recognition pathways to T cell alloreactivity. J Exp Med 1993; 177: 1643.
39. Matsuda M, Salazar F, Petersson M, et al. Interleukin-10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T-cells and down-regulates HLA class I expression. J Exp Med 1994; 180: 2371.
40. Peterssons M, Chao J, Salazar-Onfray F, et al. Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in prototype NK target YAC-1. J Immunol 1998; 161: 2099.
41. + T cell-mediated graft-versus-host disease. Transplantation 1998; 66: 1220.